Fig. 5: GLI2 acts as a downstream target of MIR31HG and promotes stemness features of NSCLC cells.

A Expression of GLI2, SOX2, and ABCG2 in NSCLC cells upon transfection of GLI2 overexpressing or knockdown plasmid respectively checked by immunoblot. B Clonal formation assay (up) and quantification (down) of NSCLC cells following GLI2 overexpression. C Clonal formation assay (left) and quantification (right) of NSCLC cells upon GLI2 knockdown compared to backbone vector-transfected cells. D Spheroid formation assay (left) and quantification (right) of NSCLC cells upon exogenous GLI2 overexpression. Scale bar, 200 µm. E Sphere formation assay (left) and quantification (right) of NSCLC cells upon GLI2 repression. Scale bar, 200 µm. F Growth curve of NSCLC cells upon enforced MIR31HG upregulation or GLI2 repression in parallel. G Clonal formation assay (left) and quantification (right) of NSCLC cells upon MIR31HG-overexpressing and GLI2-knockdown double transfection. H Spheroid formation assay (left) and quantification (right) of NSCLC cells upon MIR31HG-overexpressing and GLI2-knockdown double transfection. Scale bar, 200 µm. Data are presented as mean ± SEM; significance abundance: *p < 0.05, **p < 0.01, ***p < 0.001.